DDInter1576 DDInter1658
Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Regorafenib {u} (Compound) resembles {v} (Compound) Sorafenib
Regorafenib {u} (Compound) binds {v} (Gene) CYP2C9
Regorafenib {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 2C9 Inhibitors
Regorafenib {u} (Compound) causes {v} (Side Effect) Myocardial infarction
Regorafenib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dapagliflozin
Regorafenib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dolutegravir
Regorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Irinotecan
Regorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Abametapir
Regorafenib {u} may lead to a major life threatening interaction when taken with {v} Fondaparinux
Regorafenib {u} may lead to a major life threatening interaction when taken with {v} Venetoclax
Regorafenib (Compound) resembles Sorafenib (Compound)
Regorafenib (Compound) binds CYP2C9 (Gene)
Regorafenib (Compound) is included by Cytochrome P450 2C9 Inhibitors (Pharmacologic Class)
Regorafenib (Compound) causes Myocardial infarction (Side Effect)
Regorafenib may cause a minor interaction that can limit clinical effects when taken with Dapagliflozin
Regorafenib may cause a minor interaction that can limit clinical effects when taken with Dolutegravir
Regorafenib may cause a moderate interaction that could exacerbate diseases when taken with Irinotecan
Regorafenib may cause a moderate interaction that could exacerbate diseases when taken with Abametapir
Regorafenib may lead to a major life threatening interaction when taken with Fondaparinux
Regorafenib may lead to a major life threatening interaction when taken with Venetoclax